Last reviewed · How we verify
Gemcitabine combined with docetaxel
Gemcitabine and docetaxel work synergistically as chemotherapy agents—gemcitabine inhibits ribonucleotide reductase to disrupt DNA synthesis, while docetaxel stabilizes microtubules to prevent cell division—together targeting rapidly dividing cancer cells.
Gemcitabine and docetaxel work synergistically as chemotherapy agents—gemcitabine inhibits ribonucleotide reductase to disrupt DNA synthesis, while docetaxel stabilizes microtubules to prevent cell division—together targeting rapidly dividing cancer cells. Used for Non-small cell lung cancer, Breast cancer, Ovarian cancer.
At a glance
| Generic name | Gemcitabine combined with docetaxel |
|---|---|
| Sponsor | Hansoh BioMedical R&D Company |
| Drug class | Chemotherapy combination (nucleoside analog + taxane) |
| Target | Ribonucleotide reductase (gemcitabine); β-tubulin/microtubules (docetaxel) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that interferes with DNA replication by inhibiting ribonucleotide reductase and being incorporated into DNA, causing chain termination. Docetaxel is a taxane that binds to β-tubulin and stabilizes microtubules, preventing their disassembly and blocking mitosis. The combination exploits complementary mechanisms of action to enhance cytotoxic effects against cancer cells.
Approved indications
- Non-small cell lung cancer
- Breast cancer
- Ovarian cancer
- Pancreatic cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Fatigue
- Peripheral neuropathy
- Alopecia
- Mucositis
Key clinical trials
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer (PHASE3)
- Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer (PHASE3)
- A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
- Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy (PHASE2)
- Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: